These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18792078)

  • 21. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.
    Hoerger TJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S21-7. PubMed ID: 19536014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian methods in cost-effectiveness studies: objectivity, computation and other relevant aspects.
    Armero C; García-Donato G; López-Quílez A
    Health Econ; 2010 Jun; 19(6):629-43. PubMed ID: 19424994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian adjustment for covariate measurement errors: a flexible parametric approach.
    Hossain S; Gustafson P
    Stat Med; 2009 May; 28(11):1580-600. PubMed ID: 19226564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
    Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Semi-parametric regression models for cost-effectiveness analysis: improving the efficiency of estimation from censored data.
    Pullenayegum EM; Willan AR
    Stat Med; 2007 Jul; 26(17):3274-99. PubMed ID: 17309112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
    Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
    Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety.
    Kikuchi T; Gittins J
    Stat Med; 2009 Aug; 28(18):2293-306. PubMed ID: 19536745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
    Daimon T; Zohar S; O'Quigley J
    Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parametric modelling of cost data: some simulation evidence.
    Briggs A; Nixon R; Dixon S; Thompson S
    Health Econ; 2005 Apr; 14(4):421-8. PubMed ID: 15685641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using probabilistic terrorism risk modeling for regulatory benefit-cost analysis: application to the Western hemisphere travel initiative in the land environment.
    Willis HH; LaTourrette T
    Risk Anal; 2008 Apr; 28(2):325-39. PubMed ID: 18419652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive checking for Bayesian interim analyses in clinical trials.
    Daimon T
    Contemp Clin Trials; 2008 Sep; 29(5):740-50. PubMed ID: 18571477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The choice of sample size: a mixed Bayesian / frequentist approach.
    Pezeshk H; Nematollahi N; Maroufy V; Gittins J
    Stat Methods Med Res; 2009 Apr; 18(2):183-94. PubMed ID: 18445695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How sensitive are cost-effectiveness analyses to choice of parametric distributions?
    Thompson SG; Nixon RM
    Med Decis Making; 2005; 25(4):416-23. PubMed ID: 16061893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Presenting results of probabilistic sensitivity analysis: the incremental benefit curve.
    Bala MV; Zarkin GA; Mauskopf J
    Health Econ; 2008 Mar; 17(3):435-40. PubMed ID: 17694580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bayesian clinical trials.
    Berry DA
    Nat Rev Drug Discov; 2006 Jan; 5(1):27-36. PubMed ID: 16485344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies.
    Briggs AH; O'Brien BJ; Blackhouse G
    Annu Rev Public Health; 2002; 23():377-401. PubMed ID: 11910068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian estimation of cost-effectiveness ratios from clinical trials.
    Heitjan DF; Moskowitz AJ; Whang W
    Health Econ; 1999 May; 8(3):191-201. PubMed ID: 10348414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term cost-effectiveness of disease management in systolic heart failure.
    Miller G; Randolph S; Forkner E; Smith B; Galbreath AD
    Med Decis Making; 2009; 29(3):325-33. PubMed ID: 19147835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach.
    Vallejo-Torres L; Steuten LM; Buxton MJ; Girling AJ; Lilford RJ; Young T
    Int J Technol Assess Health Care; 2008; 24(4):459-64. PubMed ID: 18828941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.